Arylacetamide κ opioid receptor agonists with reduced cytochrome P450 2D6 inhibitory activity

被引:12
作者
Le Bourdonnec, B
Ajello, CW
Seida, PR
Susnow, RG
Cassel, JA
Belanger, S
Stabley, GJ
DeHaven, RN
DeHaven-Hudkins, DL
Dolle, RE
机构
[1] Adolor Corp, Dept Chem, Exton, PA 19341 USA
[2] Adolar Corp, Dept Pharmacol, Exton, PA 19341 USA
关键词
kappa opioid; CYP2D6;
D O I
10.1016/j.bmcl.2005.03.020
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Some K opioid receptor agonists of the arylacetamide class, for example, ICI 199441 (1), were found to strongly inhibit the activity of cytochrome P450 2D6 (CYP2D6) (1: CYP2D6 IC50 = 26 nM). Certain analogs bearing a substituted sulfonylamino group, for example, 13, were discovered to have significantly reduced CYP2D6 inhibitory activity (13: CYP2D6 IC50 > 10 mu M) while displaying high affinity toward the cloned human K opioid receptor, good kappa/delta and kappa/mu selectivity, and potent in vitro and in vivo agonist activity. (c) 2005 Elsevier Ltd. All rights reserved.
引用
收藏
页码:2647 / 2652
页数:6
相关论文
共 21 条
[1]  
AJELLO CW, 2004, 228 NAT M AM CHEM SO
[2]  
Barber A, 1997, Expert Opin Investig Drugs, V6, P1351, DOI 10.1517/13543784.6.10.1351
[3]  
Chauret N, 2001, DRUG METAB DISPOS, V29, P1196
[4]  
*CHEM COMP GROUP I, MOE VERS 2002 03
[5]   2-(3,4-DICHLOROPHENYL)-N-METHYL-N-[2-(1-PYRROLIDINYL)-1-SUBSTITUTED-ETHYL]-ACETAMIDES - THE USE OF CONFORMATIONAL-ANALYSIS IN THE DEVELOPMENT OF A NOVEL SERIES OF POTENT OPIOID KAPPA-AGONISTS [J].
COSTELLO, GF ;
JAMES, R ;
SHAW, JS ;
SLATER, AM ;
STUTCHBURY, NCJ .
JOURNAL OF MEDICINAL CHEMISTRY, 1991, 34 (01) :181-189
[6]   A NOVEL SERIES OF POTENT AND SELECTIVE AGONISTS AT THE OPIOID KAPPA-RECEPTOR [J].
COSTELLO, GF ;
MAIN, BG ;
BARLOW, JJ ;
CARROLL, JA ;
SHAW, JS .
EUROPEAN JOURNAL OF PHARMACOLOGY, 1988, 151 (03) :475-478
[7]   THE GENETIC-POLYMORPHISM OF DEBRISOQUINE SPARTEINE METABOLISM - CLINICAL ASPECTS [J].
EICHELBAUM, M ;
GROSS, AS .
PHARMACOLOGY & THERAPEUTICS, 1990, 46 (03) :377-394
[8]  
Ekins S, 2001, DRUG METAB DISPOS, V29, P936
[9]   EMD-61753 AS A FAVORABLE REPRESENTATIVE OF STRUCTURALLY NOVEL ARYLACETAMIDO-TYPE-KAPPA OPIATE RECEPTOR AGONISTS [J].
GOTTSCHLICH, R ;
ACKERMANN, KA ;
BARBER, A ;
BARTOSZYK, GD ;
GREINER, HE .
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 1994, 4 (05) :677-682
[10]   Influence of lipophilicity on the interactions of N-alkyl-4-phenyl-1,2,3,6-tetrahydropyridines and their positively charged N-alkyl-4-phenylpyridinium metabolites with cytochrome P450 2D6 [J].
Kalgutkar, AS ;
Zhou, S ;
Fahmi, OA ;
Taylor, TJ .
DRUG METABOLISM AND DISPOSITION, 2003, 31 (05) :596-605